Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 18

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 18
---
 and the successful completion of clinical trials;

•

the approval, commercialization, pricing and reimbursement of our product candidates;

•

the competitive landscape and size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;

•

estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;

•

our ability to attract and retain senior management and key employees;

•

our future business development, financial condition and results of operations;

•

future developments, trends, conditions and competitive landscape in the industry and markets in which we operate;

•

our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans, objectives and goals;

<div align='center'>9</div>

TABLE OF CONTENTS

•

costs associated with enforcing or defending against intellectual property infringement, misappropriation or violation, product liability and other claims;

•

our ability to establish and maintain collaborations or licensing agreements;

•

our ability to identify and integrate new product candidates, technologies and/or suitable acquisition targets;

•

our ability to effectively manage our growth;

•

changes to regulatory and operating conditions in our industry and markets; and

•

the potential impact of COVID-19 and other epidemics on our current and future business development, financial condition and results of operations.

The “Risk Factors” section of this prospectus, any accompanying prospectus supplement, and our annual reports on Form 20-F and reports on Form 6-K filed with the SEC and incorporated by reference into this prospectus discusses the principal contingencies and uncertainties to which we believe we are subject, which should be considered in evaluating any forward-looking statements contained or incorporated by reference in this prospectus or in any prospectus supplement.

<div align='center'>10</div>

TABLE OF CONTENTS

#### The Offering
ADSs offered by the Selling Shareholders

(i) Up to an aggregate of 1,953,124 ADSs, representing 1,953,124 ordinary shares, and (ii) up to 1,953,124 ADSs, representing 1,953,124 ordinary shares issuable upon the exercise of the Warrants.

The ADSs

Each ADS represents one ordinary share. The ADSs initially will be delivered by Deutsche Bank Trust Company Americas, as depositary (the “Depositary”).

The Depositary, as depositary, or its nominee, will be the holder of the ordinary shares underlying your ADSs and you will have rights as provided in the Deposit Agreement, dated as